Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
Ductal adenocarcinoma of the prostate is a rare histological variant that only represents <1% of prostate tumors. This histological variant has several important clinical implications with respect to their evolution, clinical prognosis, and treatment. We report the case of a 64-year-old patient w...
Saved in:
Main Authors: | Edgar Linden-Castro, Marcela Pelayo-Nieto, Alejandro Alias-Melgar, Daniel Espinosa-Perezgrovas, Ivan Ramirez-Galindo, Gabriel Catalan-Quinto |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Case Reports in Urology |
Online Access: | http://dx.doi.org/10.1155/2014/508305 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01) -
Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
by: Mike Fang, et al.
Published: (2017-01-01) -
An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer
by: Yi Wu, et al.
Published: (2025-01-01) -
New Therapeutics to Treat Castrate-Resistant Prostate Cancer
by: Ömer Acar, et al.
Published: (2013-01-01) -
New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01)